Positron emission tomography (PET) is important in the noninvasive diagnostic imaging of gliomas. There are many PET studies on glioma diagnosis based on the 2007 WHO classification; however, there are no studies on glioma diagnosis using the new classification (the 2016 WHO classification). Here, the authors investigated the relationship between uptake of 11C-methionine (MET), 11C-choline (CHO), and 18F-fluorodeoxyglucose (FDG) on PET imaging and isocitrate dehydrogenase (IDH) status (wild-type [IDH-wt] or mutant [IDH-mut]) in astrocytic and oligodendroglial tumors according to the 2016 WHO classification.
In total, 105 patients with newly diagnosed cerebral gliomas (6 diffuse astrocytomas [DAs] with IDH-wt, 6 DAs with IDH-mut, 7 anaplastic astrocytomas [AAs] with IDH-wt, 24 AAs with IDH-mut, 26 glioblastomas [GBMs] with IDH-wt, 5 GBMs with IDH-mut, 19 oligodendrogliomas [ODs], and 12 anaplastic oligodendrogliomas [AOs]) were included. All OD and AO patients had both IDH-mut and 1p/19q codeletion. The maximum standardized uptake value (SUV) of the tumor/mean SUV of normal cortex (T/N) ratios for MET, CHO, and FDG were calculated, and the mean T/N ratios of DA, AA, and GBM with IDH-wt and IDH-mut were compared. The diagnostic accuracy for distinguishing gliomas with IDH-wt from those with IDH-mut was assessed using receiver operating characteristic (ROC) curve analysis of the mean T/N ratios for the 3 PET tracers.
There were significant differences in the mean T/N ratios for all 3 PET tracers between the IDH-wt and IDH-mut groups of all histological classifications (p < 0.001). Among the 27 gliomas with mean T/N ratios higher than the cutoff values for all 3 PET tracers, 23 (85.2%) were classified into the IDH-wt group using ROC analysis. In DA, there were no significant differences in the T/N ratios for MET, CHO, and FDG between the IDH-wt and IDH-mut groups. In AA, the mean T/N ratios of all 3 PET tracers in the IDH-wt group were significantly higher than those in the IDH-mut group (p < 0.01). In GBM, the mean T/N ratio in the IDH-wt group was significantly higher than that in the IDH-mut group for both MET (p = 0.034) and CHO (p = 0.01). However, there was no significant difference in the ratio for FDG.
PET imaging using MET, CHO, and FDG was suggested to be informative for preoperatively differentiating gliomas according to the 2016 WHO classification, particularly for differentiating IDH-wt and IDH-mut tumors.
ABBREVIATIONSAA = anaplastic astrocytoma; AO = anaplastic oligodendroglioma; AUC = area under the curve; CHO = 11C-choline; DA = diffuse astrocytoma; DOR = diagnostic odds ratio; FDG = 18F-fluorodeoxyglucose; GBM = glioblastoma; IDH = isocitrate dehydrogenase; IDH-mut = mutant IDH; IDH-wt = wild-type IDH; MET = 11C-methionine; OD = oligodendroglioma; PET = positron emission tomography; R-2HG = R-2-hydroxyglutarate; ROC = receiver operating characteristic; ROI = region of interest; SUV = standardized uptake value; T/N = tumor maximal SUV/normal brain cortex mean SUV.
BeikoJSukiDHessKRFoxBDCheungVCabralM: IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol16:81–912014
BeikoJ, SukiD, HessKR, FoxBD, CheungV, CabralM, : IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. 16:81–91, 20142430571910.1093/neuonc/not159)| false
BratDJAldapeKColmanHHollandECLouisDNJenkinsRB: cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol136:805–8102018
CicuendezMLorenzo-BosquetCCuberas-BorrósGMartinez-RicarteFCorderoEMartinez-SaezE: Role of [11C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clin Neurol Neurosurg139:328–3332015
CicuendezM, Lorenzo-BosquetC, Cuberas-BorrósG, Martinez-RicarteF, CorderoE, Martinez-SaezE, : Role of [11C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. 139:328–333, 201510.1016/j.clineuro.2015.10.035)| false
DankbaarJW, SnijdersTJ, RobePA, SeuteT, EppingaW, HendrikseJ, : The use of 18F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. 125:167–175, 201510.1007/s11060-015-1883-126384811)| false
DelevD, HeilandDH, FrancoP, ReinacherP, MaderI, StaszewskiO, : Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. 141:223–233, 201910.1007/s11060-018-03030-w30467813)| false
Eckel-PassowJE, LachanceDH, MolinaroAM, WalshKM, DeckerPA, SicotteH, : Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. 372:2499–2508, 20152606175310.1056/NEJMoa1407279)| false
KatoTShinodaJNakayamaNMiwaKOkumuraAYanoH: Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol29:1176–11822008
LouisDNPerryAReifenbergerGvon DeimlingAFigarella-BrangerDCaveneeWK: The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol131:803–8202016
LouisDN, PerryA, ReifenbergerG, von DeimlingA, Figarella-BrangerD, CaveneeWK, : The 2016 World Health Organization classification of tumors of the central nervous system: a summary. 131:803–820, 201610.1007/s00401-016-1545-127157931)| false
MinamimotoRSaginoyaTKondoCTomuraNItoKMatsuoY: Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment. PLoS One10:e01325152015
OgawaTInugamiAHatazawaJKannoIMurakamiMYasuiN: Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and l-methyl-11C-methionine. AJNR Am J Neuroradiol17:345–3531996
OkamotoSShigaTHattoriNKuboNTakeiTKatohN: Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med25:213–2202011
OkamotoS, ShigaT, HattoriN, KuboN, TakeiT, KatohN, : Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. 25:213–220, 20112118866010.1007/s12149-010-0450-2)| false
OkitaYKinoshitaMGotoTKagawaNKishimaHShimosegawaE: 11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. Neuroimage49:2977–29822010
OkitaY, KinoshitaM, GotoT, KagawaN, KishimaH, ShimosegawaE, : 11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. 49:2977–2982, 201010.1016/j.neuroimage.2009.11.024)| false
RottenburgerC, HentschelM, KellyT, TrippelM, BrinkI, ReithmeierT, : Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. 36:639–642, 20112171601210.1097/RLU.0b013e3182175840)| false
SahmF, ReussD, KoelscheC, CapperD, SchittenhelmJ, HeimS, : Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. 128:551–559, 201410.1007/s00401-014-1326-725143301)| false
SatoNSuzukiMKuwataNKurodaKWadaTBeppuT: Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev22:210–2141999
SinghalT, NarayananTK, JacobsMP, BalC, MantilJC: 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. 53:1709–1715, 201210.2967/jnumed.111.10253323055534)| false
TakenakaSAsanoYShinodaJNomuraYYonezawaSMiwaK: Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo)54:280–2892014
TerakawaYTsuyuguchiNIwaiYYamanakaKHigashiyamaSTakamiT: Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med49:694–6992008
TerakawaY, TsuyuguchiN, IwaiY, YamanakaK, HigashiyamaS, TakamiT, : Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. 49:694–699, 200810.2967/jnumed.107.04808218413375)| false
UllrichRT, KrachtL, BrunnA, HerholzK, FrommoltP, MileticH, : Methyl-l-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. 50:1962–1968, 200910.2967/jnumed.109.06590419910435)| false
WellerMWeberRGWillscherERiehmerVHentschelBKreuzM: Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol129:679–6932015
WiestlerBCapperDSillMJonesDTWHovestadtVSturmD: Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol128:561–5712014
WiestlerB, CapperD, SillM, JonesDTW, HovestadtV, SturmD, : Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. 128:561–571, 201410.1007/s00401-014-1315-x25008768)| false